U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07379151) titled 'Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine' on Jan. 23.
Brief Summary: This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
Study Start Date: March, 2026
Study Type: OBSERVATIONAL
Condition:
Meningoccocal Disease
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Serum Institute of India Pvt. Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....